Corner Therapeutics aims to induce durable memory T cells and antibody responses through use of multi-purpose immunotherapies for cancers and infectious diseases. They leverage their Hyperactivation Platform to improve the ability of dendritic cells to enhance T and B cell-mediated immunity through inflammasome activation. Their Catalytic Adjuvant Platform is used to develop vaccines for the prevention of infections and treatment of cancers that are delivered to cells via lipid nanoparticles. Corner’s co-founders are professors at Harvard, Jeff Karp and Jonathan Kagan, and previous CSO at Lyndra Therapeutics and Cocoon Biotech, Andrew Bellinger.

Corner Therapeutics

Founded: 2020
Location: Watertown, MA
Employee range: 11 - 50
Clinical stage: RD
Therapy area: Oncology
Drug types: ONC, INF
Lead product: Undisclosed
Investors: Ziff Capital Partners

Drug notes:

About:

Jobs: